-
1دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
2
المؤلفون: J Posner, Antoine Italiano, J Garcia-Corbacho, H-T. Arkenau, D Tosi, Richard H. Wilson, Antoine Adenis, Michael Flynn, S Deva, A Arimura, Gabriel Mak, Maud Toulmonde, Ken Donaldson, I Kawabata, Ruth Plummer, Richard D. Baird, Martin Forster, James Spicer
المساهمون: Institut Bergonié [Bordeaux], UNICANCER, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Université de Lille-UNICANCER, Baird, Richard [0000-0001-7071-6483], Apollo - University of Cambridge Repository
المصدر: Arkenaua, H-T, Italiano, A, Mak, G, Toulmonde, M, Baird, R D, Garcia-Corbacho, J, Plummer, R, Flynn, M, Forster, M, Wilson, R H, Tosi, D, Adenis, A, Donaldson, K, Posner, J, Kawabata, I, Arimura, A, Deva, S & Spicer, J 2018, ' An Extended Phase Ib Study of Epertinib, an Orally Active Reversible Dual EGFR/HER2 Tyrosine Kinase Inhibitor, in Patients with Solid Tumours ', European Journal of Cancer, vol. 103, pp. 17-23 . https://doi.org/10.1016/j.ejca.2018.07.134
European Journal of Cancer
European Journal of Cancer, Elsevier, 2018, 103, pp.17-23. ⟨10.1016/j.ejca.2018.07.134⟩
European Journal of Cancer, 2018, 103, pp.17-23. ⟨10.1016/j.ejca.2018.07.134⟩مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Loperamide, medicine.drug_class, EGFR, Tyrosine kinase inhibitor, [SDV.CAN]Life Sciences [q-bio]/Cancer, Epertinib, Gastroenterology, Tyrosine-kinase inhibitor, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Pharmacokinetics, Neoplasms, Internal medicine, HER2, Humans, Medicine, In patient, 030212 general & internal medicine, Dosing, Adverse effect, skin and connective tissue diseases, Protein Kinase Inhibitors, Aged, Aged, 80 and over, business.industry, Middle Aged, medicine.disease, 3. Good health, Treatment Outcome, S-222611, Oncology, Tolerability, 030220 oncology & carcinogenesis, Quinazolines, Female, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, medicine.drug
وصف الملف: application/pdf
-
3
المؤلفون: Ken ichi Nezasa, Eugene P. Frenkel, Toru Wada, Satomi Shinonome, Keiji Dohi, Kanji Hojo, Michitaka Shichijo, Koichi Masuno, T. Yamada, Motofumi Iguchi, Norihito Sato, Hidekazu Tanaka, Tatsuya Sugimoto, Shuji Yonezawa, Yukichi Ishioka, Kenji Matsuo, Makiko Inoue, Michinari Hirata
المصدر: Cancer Science
مصطلحات موضوعية: Cancer Research, kinase inhibitor, Receptor, ErbB-2, medicine.drug_class, Afatinib, Mice, Nude, Antineoplastic Agents, Mice, SCID, Pharmacology, Lapatinib, Tyrosine-kinase inhibitor, Mice, Cell Line, Tumor, medicine, Animals, Humans, Growth factor receptor inhibitor, Epidermal growth factor receptor, Kinase activity, skin and connective tissue diseases, Protein Kinase Inhibitors, biology, human epidermal growth factor receptor 2, Original Articles, General Medicine, Xenograft Model Antitumor Assays, ErbB Receptors, Disease Models, Animal, S-222611, Oncology, Neratinib, Quinazolines, biology.protein, Drug Screening Assays, Antitumor, epidermal growth factor receptor, Antitumor activity, Tyrosine kinase, medicine.drug
-
4دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
5
المؤلفون: Arkenau, H-T, Italiano, A, Mak, G, Toulmonde, M, Baird, RD, Garcia-Corbacho, J, Plummer, R, Flynn, M, Forster, M, Wilson, RH, Tosi, D, Adenis, A, Donaldson, K, Posner, J, Kawabata, I, Arimura, A, Deva, S, Spicer, J
مصطلحات موضوعية: Adult, Aged, 80 and over, Male, EGFR, Tyrosine kinase inhibitor, Epertinib, Middle Aged, 3. Good health, S-222611, Treatment Outcome, HER2, Neoplasms, Quinazolines, Humans, Female, Protein Kinase Inhibitors, Aged
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::eea94f55dbfa07e126c9292ef18ed59a